Abstract: Provided herein is a technology for an Autonomous Vehicle Cloud System (AVCS). This AVCS provides sensing, data fusion, prediction, decision-making, and/or control instructions for specific vehicles at a microscopic level based on data from one or more of other vehicles, roadside unit (RSU), cloud-based platform, and traffic control center/traffic control unit (TCC/TCU). Specifically, the AVs can be effectively and efficiently operated and controlled by the AVCS. The AVCS provides individual vehicles with detailed time-sensitive control instructions for fulfilling driving tasks, including car following, lane changing, route guidance, and other related information. The AVCS is configured to predict individual vehicle behavior and provide planning and decision-making at a microscopic level. In addition, the AVCS is configured to provide one or more of virtual traffic light management, travel demand assignment, traffic state estimation, and platoon control.

Abstract: Provided herein is a technology for an Autonomous Vehicle Intelligent System (AVIS), which facilitates vehicle operations and control for autonomous driving. The AVIS and related methods provide vehicles with vehicle-specific information for a vehicle to perform driving tasks such as car following, lane changing, and route guidance. The AVIS comprises an onboard unit (OBU), wherein the OBU comprises a communication module communicating with one or more of other autonomous vehicles (AV), a roadside unit (RSU), a cloud platform, and a traffic control center/traffic control unit (TCC/TCU). The AVIS implements one or more of the following functions: sensing, prediction, decision-making, and vehicle control using onboard information and vehicle-specific information received from other AVs, the RSU, the cloud platform, and/or the TCC/TCU.

Abstract: The invention provides systems and methods for a computing power allocation system for autonomous driving (CPAS-AD), which is a component of an Intelligent Road Infrastructure System (IRIS). The CPAS-AD incorporates advanced computing capabilities that effectively allocate computational power for sensing, prediction, planning, decision-making, and control functions to enable end-to-end driving functions. In addition to the vehicle, the CPAS-AD can acquire additional computation resources from one or more of: (a) a roadside unit (RSU) network, (b) a cloud platform, (c) a traffic control center/traffic control unit (TCC/TCU), and (d) a traffic operations center (TOC). Additionally, tailored to different traffic scenarios, the CPAS-AD can allocate data and computation resources (including but not limited to CPU and GPU) for vehicle sensing, prediction, planning, decision-making, and control functions, thereby enabling safe and efficient autonomous driving.

Abstract: The invention provides systems and methods for a function-based computing power allocation system (FCPAS), which is a component of an Intelligent Road Infrastructure System (IRIS). The FCPAS incorporates advanced computing capabilities that effectively allocate computational power for prediction, planning, and decision making functions. Specifically, through the FCPAS, an AV can acquire additional computational resources for vehicle prediction, planning, and decision-making functions, thereby enabling safe and efficient autonomous driving. Additionally, tailored to different traffic scenarios, the FCPAS can allocate data and computational resources (including but not limited to CPU and GPU) for vehicle automation.

Abstract: Provided are new classes of reconfigurable, multistable metasurfaces using the physics of colloids confined within nematic liquid crystals (NLCs). The colloids are physically moved from one stable location to another as defined by NLC-colloid interactions by external switching fields. These colloids can be scatterers within reconfigurable metasurfaces with electromagnetic (EM) responses that change with colloid location. because the colloids are moved between stable loci, these metasurfaces are also multistable, and require energy input only when changing colloid position. Furthermore, because the colloids can be returned to their original positions by simply reversing the switching field, all changes in EM responses are entirely reversible.

Abstract: Provided are compositions that include a nematic colloid, the nematic colloid comprising a nematic liquid crystal and a key colloid; and a lock colloid, the lock colloid optionally having at least two arms extending therefrom, the lock colloid being configured for assembly with the key colloid of the nematic colloid, the assembly optionally being mediated by a dipole interaction between the colloid and the lock colloid, by a disinclination line of the nematic colloid, or any combination thereof. Also provided are related methods. The disclosed compositions and methods can be used to, e.g., assemble chain and lattice structures from the key colloids by exploiting disinclination lines and dipole defects of the components of the compositions.

Abstract: The present invention relates to a formulation comprising a PD-L1/LAG-3 bispecific antibody, and particularly to a pharmaceutical formulation comprising a PD-L1/LAG-3 bispecific antibody, a buffer, a stabilizer, a surfactant and a chelating agent. Furthermore, the present invention further relates to therapeutic or prophylactic use of these formulations.

Abstract: Provided are compositions that include a nematic colloid, the nematic colloid comprising a nematic liquid crystal and a key colloid; and a lock colloid, the lock colloid optionally having at least two arms extending therefrom, the lock colloid being configured for assembly with the key colloid of the nematic colloid, the assembly optionally being mediated by a dipole interaction between the colloid and the lock colloid, by a disinclination line of the nematic colloid, or any combination thereof. Also provided are related methods. The disclosed compositions and methods can be used to, e.g., assemble chain and lattice structures from the key colloids by exploiting disinclination lines and dipole defects of the components of the compositions.

Abstract: The present invention relates to formulations comprising an anti-LAG-3 antibody, and in particular to pharmaceutical formulations comprising an antibody specifically binding to LAG-3 molecules, a buffer, a stabilizer and a surfactant. Furthermore, the present invention also relates to therapeutic or prophylactic use of these formulations.